SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Icosavax, Inc. (ICVX) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+76.4%).
- Analyst consensus target $27.00 (+76.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 55/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ICVX
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1,045.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.23
Book Value / Share$0.00
Revenue / Share$0.01
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$27.00 (+76.4%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.51 |
$0.00 |
$-5.2M |
- |
| 2020 |
$-6.67 |
$1.62M |
$-19.19M |
-1187.2% |
| 2021 |
$-3.78 |
$7.8M |
$-68M |
-871.6% |
| 2022 |
$-2.23 |
$582K |
$-88.46M |
-15199% |
